{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:40:23Z","timestamp":1776692423661,"version":"3.51.2"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,8]]},"DOI":"10.7759\/cureus.26663","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T17:01:12Z","timestamp":1657299672000},"source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of a Patient With Non-Myoinvasive Uterine Serous Carcinoma Confined to a Polyp and Positive Peritoneal Washings With Somatic ARHGAP35 and KRAS Mutations"],"prefix":"10.7759","author":[{"given":"Sierra M","family":"Silverwood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Lagstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John I","family":"Risinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Gressel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel RL","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021, 71:7-33. 10.3322\/caac.21654","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/GRF.0b013e318218c755","article-title":"Uterine papillary serous carcinoma","volume":"54","author":"Moore KN","year":"2011","unstructured":"Moore KN, Fader AN. Uterine papillary serous carcinoma. Clin Obstet Gynecol. 2011, 54:278-91. 10.1097\/GRF.0b013e318218c755","journal-title":"Clin Obstet Gynecol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.09.012","article-title":"Uterine papillary serous cancer: a review of the literature","volume":"127","author":"del Carmen MG","year":"2012","unstructured":"del Carmen MG, Birrer M, Schorge JO. Uterine papillary serous cancer: a review of the literature. Gynecol Oncol. 2012, 127:651-61. 10.1016\/j.ygyno.2012.09.012","journal-title":"Gynecol Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(90)90116-3","article-title":"Prognostic value of peritoneal cytology in endometrial carcinoma","volume":"36","author":"Grimshaw RN","year":"1990","unstructured":"Grimshaw RN, Carl Tupper W, Fraser RC, Tompkins MG, Jeffrey JF. Prognostic value of peritoneal cytology in endometrial carcinoma. Gynecologic Oncology. 1990, 36:97-100. 10.1016\/0090-8258(90)90116-3","journal-title":"Gynecologic Oncology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600698","article-title":"Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus","volume":"88","author":"Kasamatsu T","year":"2003","unstructured":"Kasamatsu T, Onda T, Katsumata N, et al.. Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus. Br J Cancer. 2003, 88:245-50. 10.1038\/sj.bjc.6600698","journal-title":"Br J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800342","article-title":"Upstaging based solely on positive peritoneal washing does not affect outcome in endometrial cancer","volume":"18","author":"Fadare O","year":"2005","unstructured":"Fadare O, Mariappan MR, Hileeto D, Wang S, McAlpine JN, Rimm DL. Upstaging based solely on positive peritoneal washing does not affect outcome in endometrial cancer. Mod Pathol. 2005, 18:673-80. 10.1038\/modpathol.3800342","journal-title":"Mod Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium","volume":"105","author":"Pecorelli S","year":"2009","unstructured":"Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009, 105:103-4. 10.1016\/j.ijgo.2009.02.012","journal-title":"Int J Gynaecol Obstet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.01.007","article-title":"Re-thinking the prognostic significance of positive peritoneal cytology in endometrial cancer","volume":"161","author":"Takenaka M","year":"2021","unstructured":"Takenaka M, Kamii M, Iida Y, et al.. Re-thinking the prognostic significance of positive peritoneal cytology in endometrial cancer. Gynecol Oncol. 2021, 161:135-42. 10.1016\/j.ygyno.2021.01.007","journal-title":"Gynecol Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.02.012","article-title":"Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer","volume":"149","author":"Matsuo K","year":"2018","unstructured":"Matsuo K, Yabuno A, Hom MS, et al.. Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer. Gynecol Oncol. 2018, 149:301-9. 10.1016\/j.ygyno.2018.02.012","journal-title":"Gynecol Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.11.601","article-title":"Prognosis and treatment of positive peritoneal cytology in\u00a0early endometrial cancer: matched cohort analyses from\u00a0the National Cancer Database","volume":"218","author":"Seagle BL","year":"2018","unstructured":"Seagle BL, Alexander AL, Lantsman T, Shahabi S. Prognosis and treatment of positive peritoneal cytology in\u00a0early endometrial cancer: matched cohort analyses from\u00a0the National Cancer Database. Am J Obstet Gynecol. 2018, 218:329.e1-329.e15. 10.1016\/j.ajog.2017.11.601","journal-title":"Am J Obstet Gynecol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000072","article-title":"Does positive peritoneal cytology not affect the prognosis for stage I uterine endometrial cancer?: the remaining controversy and review of the literature","volume":"24","author":"Shiozaki T","year":"2014","unstructured":"Shiozaki T, Tabata T, Yamada T, Yamamoto Y, Yamawaki T, Ikeda T. Does positive peritoneal cytology not affect the prognosis for stage I uterine endometrial cancer?: the remaining controversy and review of the literature. Int J Gynecol Cancer. 2014, 24:549-55. 10.1097\/IGC.0000000000000072","journal-title":"Int J Gynecol Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.21399","article-title":"Positive peritoneal cytology in patients with endometrial cancer: continued controversy despite shift in staging","volume":"122","author":"del Carmen MG","year":"2014","unstructured":"del Carmen MG. Positive peritoneal cytology in patients with endometrial cancer: continued controversy despite shift in staging. Cancer Cytopathol. 2014, 122:315-6. 10.1002\/cncy.21399","journal-title":"Cancer Cytopathol"},{"key":"ref13","article-title":"NCCN Guidelines Version 1.2022 Uterine","author":"Nicole McMillian N","year":"2021","unstructured":"Nicole McMillian N, Angela Motter M, Frederick P, et al.. NCCN Guidelines Version 1.2022 Uterine. National Comprehensive Cancer Network (NCCN). 2021, Accessed: January 18, 2022: https:\/\/www.nccn.org\/home\/member-."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth C","year":"2013","unstructured":"Kandoth C, Schultz N, Cherniack AD, et al.. Integrated genomic characterization of endometrial carcinoma. Nature. 2013, 497:67-73. 10.1038\/nature12113","journal-title":"Nature"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"","volume":"15","year":"1983","unstructured":"Bokhman J v. Two pathogenetic types of endometrial carcinoma. Gynecologic oncology. 1983, 15.10-17. 10.1016\/0090-8258(83)90111-7","journal-title":"Bokhman J v. Two pathogenetic types of endometrial carcinoma. Gynecologic oncology"},{"key":"ref16","article-title":"Endometrial carcinoma: two diseases? Cancer Detection and Prevention. 1987;10(3-4): 237-246. Accessed","author":"Deligdisch L","unstructured":"Deligdisch L, Holinka CF. Endometrial carcinoma: two diseases? Cancer Detection and Prevention. 1987;10(3-4): 237-246. Accessed. Accessed: January 17, 2022: https:\/\/europepmc.org\/article\/med\/3568022."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2021.100830","article-title":"Impact of positive cytology in uterine serous carcinoma: A reassessment","volume":"37","author":"Corey L","year":"2021","unstructured":"Corey L, Fucinari J, Elshaikh M, et al.. Impact of positive cytology in uterine serous carcinoma: A reassessment. Gynecol Oncol Rep. 2021, 37:100830. 10.1016\/j.gore.2021.100830","journal-title":"Gynecol Oncol Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.09.026","article-title":"Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer","volume":"128","author":"Garg G","year":"2013","unstructured":"Garg G, Gao F, Wright JD, Hagemann AR, Mutch DG, Powell MA. Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer. Gynecol Oncol. 2013, 128:77-82. 10.1016\/j.ygyno.2012.09.026","journal-title":"Gynecol Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2020.10.045","article-title":"Proposal of an endometrial cancer staging schema with stage-specific incorporation of malignant peritoneal cytology","volume":"224","author":"Matsuo K","year":"2021","unstructured":"Matsuo K, Matsuzaki S, Roman LD, Klar M, Wright JD. Proposal of an endometrial cancer staging schema with stage-specific incorporation of malignant peritoneal cytology. Am J Obstet Gynecol. 2021, 224:319-21. 10.1016\/j.ajog.2020.10.045","journal-title":"Am J Obstet Gynecol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.06.012","article-title":"Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy","volume":"98","author":"Kelly MG","year":"2005","unstructured":"Kelly MG, O'malley DM, Hui P, et al.. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol. 2005, 98:353-9. 10.1016\/j.ygyno.2005.06.012","journal-title":"Gynecol Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.10.017","article-title":"Clinical calculator predictive of chemotherapy benefit in stage 1A uterine papillary serous cancers","volume":"156","author":"Mysona DP","year":"2020","unstructured":"Mysona DP, Tran LK, Tran PM, et al.. Clinical calculator predictive of chemotherapy benefit in stage 1A uterine papillary serous cancers. Gynecol Oncol. 2020, 156:77-84. 10.1016\/j.ygyno.2019.10.017","journal-title":"Gynecol Oncol"},{"key":"ref22","unstructured":"Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma | Elsevier Enhanced Reader. Accessed. Accessed. August 21, 2021: https:\/\/reader.elsevier.com\/reader\/sd\/pii\/S2352578919300141."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.07.016","article-title":"Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study","volume":"159","author":"Erickson BK","year":"2020","unstructured":"Erickson BK, Najjar O, Damast S, et al.. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. Gynecol Oncol. 2020, 159:17-22. 10.1016\/j.ygyno.2020.07.016","journal-title":"Gynecol Oncol"},{"key":"ref24","unstructured":"Mechanisms of Resistance to HER2-targeted Therapies in HER2-amplified Uterine Serous Carcinoma, and Strategies to Overcome It - Gulden Menderes - Discovery Medicine. Accessed August 13. (2021). https.\/\/www.discoverymedicine.com\/Gulden-Menderes\/2018\/08\/mechanisms-of-resistance-to-her2-targeted-therapies-in-uter...."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0994","article-title":"PIK3CA mutations in patients with advanced cancers treated with PI3K\/AKT\/mTOR axis inhibitors","volume":"10","author":"Janku F","year":"2011","unstructured":"Janku F, Tsimberidou AM, Garrido-Laguna I, et al.. PIK3CA mutations in patients with advanced cancers treated with PI3K\/AKT\/mTOR axis inhibitors. Mol Cancer Ther. 2011, 10:558-65. 10.1158\/1535-7163.MCT-10-0994","journal-title":"Mol Cancer Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2\/neu","volume":"36","author":"Fader AN","year":"2018","unstructured":"Fader AN, Roque DM, Siegel E, et al.. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2\/neu. J Clin Oncol. 2018, 36:2044-51. 10.1200\/JCO.2017.76.5966","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.11.016","article-title":"Stage II uterine papillary serous carcinoma: Carboplatin\/paclitaxel chemotherapy improves recurrence and survival outcomes","volume":"112","author":"Fader AN","year":"2009","unstructured":"Fader AN, Nagel C, Axtell AE, et al.. Stage II uterine papillary serous carcinoma: Carboplatin\/paclitaxel chemotherapy improves recurrence and survival outcomes. Gynecol Oncol. 2009, 112:558-62. 10.1016\/j.ygyno.2008.11.016","journal-title":"Gynecol Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2021-002753","article-title":"Uterine serous carcinoma: key advances and novel treatment approaches","volume":"31","author":"Ferriss JS","year":"2021","unstructured":"Ferriss JS, Erickson BK, Shih IM, Fader AN. Uterine serous carcinoma: key advances and novel treatment approaches. Int J Gynecol Cancer. 2021, 31:1165-74. 10.1136\/ijgc-2021-002753","journal-title":"Int J Gynecol Cancer"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2009.5","article-title":"Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis","volume":"22","author":"Catasus L","year":"2009","unstructured":"Catasus L, Gallardo A, Cuatrecasas M, Prat J. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol. 2009, 22:522-9. 10.1038\/modpathol.2009.5","journal-title":"Mod Pathol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.306","article-title":"PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2\/neu overexpressing uterine serous carcinomas","volume":"113","author":"Black JD","year":"2015","unstructured":"Black JD, Lopez S, Cocco E, et al.. PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2\/neu overexpressing uterine serous carcinomas. Br J Cancer. 2015, 113:1020-6. 10.1038\/bjc.2015.306","journal-title":"Br J Cancer"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_SUPPL.6009","article-title":"A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma. https:\/\/doi.org\/101200\/JCO20203815_suppl6009","volume":"38","author":"Liu JF","year":"2020","unstructured":"Liu JF, Xiong N, Campos SM, et al.. A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma. https:\/\/doi.org\/101200\/JCO20203815_suppl6009. 2020, 38:6009-6009. 10.1200\/JCO.2020.38.15_SUPPL.6009"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao J","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, et al.. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013, 6:pl1. 10.1126\/scisignal.2004088","journal-title":"Sci Signal"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic Signaling Pathways in The Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega F","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J, et al.. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018, 173:321-337.e10. 10.1016\/j.cell.2018.03.035","journal-title":"Cell"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.010","article-title":"Integrated Molecular Characterization of Uterine Carcinosarcoma","volume":"31","author":"Cherniack AD","year":"2017","unstructured":"Cherniack AD, Shen H, Walter V, et al.. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell. 2017, 31:411-23. 10.1016\/j.ccell.2017.02.010","journal-title":"Cancer Cell"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/cells8040351","article-title":"p190RhoGAPs, the ARHGAP35- and ARHGAP5-Encoded Proteins, in Health and Disease","volume":"8","author":"H\u00e9raud C","year":"2019","unstructured":"H\u00e9raud C, Pinault M, Lagr\u00e9e V, Moreau V. p190RhoGAPs, the ARHGAP35- and ARHGAP5-Encoded Proteins, in Health and Disease. Cells. 2019, 8:10.3390\/cells8040351","journal-title":"Cells"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1159\/000134729","article-title":"Assignment of the ARHA and GPX1 genes to human chromosome bands 3p21.3 by in situ hybridization and with somatic cell hybrids","volume":"79","author":"Kiss C","year":"1997","unstructured":"Kiss C, Li J, Szeles A, et al.. Assignment of the ARHA and GPX1 genes to human chromosome bands 3p21.3 by in situ hybridization and with somatic cell hybrids. Cytogenet Cell Genet. 1997, 79:228-30. 10.1159\/000134729","journal-title":"Cytogenet Cell Genet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/96996-evaluation-of-a-patient-with-non-myoinvasive-uterine-serous-carcinoma-confined-to-a-polyp-and-positive-peritoneal-washings-with-somatic-arhgap35-and-kras-mutations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:39:05Z","timestamp":1707507545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/96996-evaluation-of-a-patient-with-non-myoinvasive-uterine-serous-carcinoma-confined-to-a-polyp-and-positive-peritoneal-washings-with-somatic-arhgap35-and-kras-mutations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":36,"URL":"https:\/\/doi.org\/10.7759\/cureus.26663","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,8]]}}}